EquiLend Data & Analytics presents a comparative analysis revealing critical lockup dynamics in securities lending markets. CoreWeave (CRWV) demonstrated extreme volatility around its accelerated lockup expiration on August 14, 2025, with borrowing costs peaking at 44,324 bps before collapsing. CRCL exhibits similar pre-lockup warning signals with utilization remaining elevated, suggesting potential for comparable volatility. Daily monitoring of borrowing metrics is essential to stay ahead of lockup-driven supply shocks.

In this EquiLend Data & Analytics Market Flash, we provide a concluding analysis of the significant build-up of short interest in Paramount Global (PARA).

In our latest EquiLend Data & Analytics Market Flash, we analyze the multi-month build-up of short interest in Baxter International Inc. (BAX).

A key theme emerging in the market year-to-date is the notable underperformance of consensus bearish trades.

Insight JULY 25, 2025 Market Flash Market Flash on Kohl’s (KSS) and Opendoor (OPEN) The Return of Meme Stock Mania Recent market activity has shown how heavily shorted stocks can be affected by coordinated retail trading campaigns. Our analysis of Kohl’s Corporation (KSS) and Opendoor Technologies (OPEN) identifies patterns in securities finance metrics that indicate […]

Lucid Motors price soared nearly 40% following its robotaxi deal with Uber, but are the shorts positioning for a fall?

EquiLend’s data for Unusual Machines (UMAC) signaled investor skepticism ahead of a recent price drop.

As the price of Cyngn Inc. (CYN) rallied 120% in recent weeks following news of its partnership with Nvidia, EquiLend Data & Analytics identified increasing short positions.

EquiLend Data & Analytics surfaced elevated short interest in NOVA, averaging 28.8%, well before the June 9 bankruptcy filing.

This Hong Kong-listed pharmaceutical stock climbed 30% in 3 weeks — yet short positioning rose sharply: borrow quantity increased 182% and utilization more than doubled.

UnitedHealth Group (TICKER: UNH) shares fell from $600 on April 11 to $275 as of May 15 erasing over $300 billion in market value as rising medical costs, regulatory pressures and a Department of Justice criminal investigation into possible Medicare fraud undermined investor confidence.

EquiLend Data & Analytics identifies NetClass Technology as a prime short squeeze candidate, with its short squeeze score at 90.

EquiLend Data & Analytics identifies Regencell Bioscience as a prime short squeeze candidate, with its short squeeze score at 88.

EquiLend Data & Analytics identifies Janover Inc as a prime short squeeze candidate, as the EquiLend Short Squeeze Score surged to 86 indicating extreme potential for continued short covering.

EquiLend Data & Analytics identifies Summit Therapeutics as a prime short squeeze candidate, with its squeeze score surging 43.0 points to 66 in just one month. With utilization approaching 78.98% and elevated borrow fees, short sellers are facing mounting pressure as positive clinical trial results drive momentum.